Translate Bio, an early-stage biotech developing mRNA therapies for genetic diseases, raised $122 million by offering 9.4 million shares at $13, within the range of $12 to $14. The company had orginally planned to sell 7.7 million shares. Translate Bio plans to list on the Nasdaq under the symbol TBIO. Citi, Leerink Partners and Evercore ISI acted as lead managers on the deal.
